Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio ...

Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. ("Zydus Group"), today announced that the U.S. Food and Drug Administration (FDA ...

When someone you love discloses an eating disorder, your response matters more than you think. Here’s what to know and how to ...

New PDUFA Target Action Date of January 14, 2026 set by FDAMIAMI, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc.

Dyne Therapeutics, Inc.’s 2026 outlook with key DYNE-101/251 data, FDA submission plans, and extended cash runway. Click for ...

The latest data released at ASH 2025 offer new combination therapies for the treatment of multiple myeloma and new insights into the disease.

Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population.

Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences (Zydus Group), today announced that the U.S. Food and Drug Administration (FDA) has ...

("GenSci"), RTW Investments, LP ("RTW"), and Yarrow Bioscience, Inc. ("Yarrow") today announced an exclusive global ex-China license agreement for GS-098, a clinical-stage, first-in-class, humanized ...

After its disastrous phase III eye disease trials, Opthea will repurpose its lead asset to treat a rare lung disease the ...

Some of our most promising biotechs have taken part in a pre yuletide rush of clinical trial updates – and there is much to ...

New trials reveal INCA033989 shows promise for treating CALR exon 9-mutated myelofibrosis, demonstrating efficacy and tolerability in patients.